Development of Candida albicans colitis in a child undergoing steroid therapy for ulcerative colitis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 51, Issue 1, 2010, Pages 96-99

  Kudo, Takahiro ^a   Aoyagi, Yoh ^a   Fujii, Tohru ^a   Ohtsuka, Yoshikazu ^a   Nagata, Satoru ^a   Shimizu, Toshiaki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; FOSFOMYCIN; ITRACONAZOLE; MESALAZINE; PREDNISOLONE;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BLOOD ANALYSIS; CANDIDA ALBICANS; CANDIDA ALBICANS COLITIS; CANDIDIASIS; CARDIOPULMONARY FUNCTION; CASE REPORT; COLONOSCOPY; DIARRHEA; DRUG DOSE INCREASE; ENTEROCOLITIS; FECES CULTURE; HUMAN; MALE; NONHUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROCTITIS; RECTUM HEMORRHAGE; STEROID THERAPY; ULCERATIVE COLITIS;

ADOLESCENT; BETAMETHASONE; CANDIDA ALBICANS; CANDIDIASIS; COLITIS; COLITIS, ULCERATIVE; GLUCOCORTICOIDS; HUMANS; MALE; OPPORTUNISTIC INFECTIONS; PREDNISOLONE;

CANDIDA ALBICANS;

EID: 77954423330     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31818de1ba     Document Type: Article

References (19)

1. Tomomasa T, Kobayashi A, Ushijima K, et al. Guidelines for treatment of ulcerative colitis in children. Pediatrics International 2004;46: 494-496
2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369: 1641-1657
3. Meldy JC. Systemic corticosteroid therapy; pharmacology and end-crinologic considerations. Ann Intern Med 1974;81:505.
4. Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002;78:455-459
5. Milne LJR, Crompton GK. Beclomethasone Dipropionate and Orophar-yngeal Candidiasis. BMJ 1974;3:797-798
6. Chiu JT, Wells I, Novey HS. Incidence of fungal precipitins in patients treated with beclomethasone dipropionate aerosol. Ann Allergy 1981;46:137-139
7. Ellepola ANB, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis 2001;7:211-216
8. Zwolinska-Wcislo M, Budak A, Trojanowska D, et al. The influence of Candida albicans on the course of ulcerative colitis. Przegl Lek 2006;63:533-538
9. Garcia-Osogobio S, Takahashi T, Gamboa-Dominguez A, et al. Toxic pseudomembranous colitis in a patient with ulcerative colitis. Inflamm Bowel Dis 2000;6:188-190
10. Bolton RP, Sherriff RJ, Read AE. Clostridium difficile associated diarrhea: a role in inflammatory bowel disease? Lancet 1980;I:383-384
11. Meyers S, Mayer L, Bottone E, et al. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterol-ogy 1981;80:697-700.
12. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997;92: 739-751
13. LaMont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 1980;I:381-383
14. Trudel JL, Deschenes M. toxic megacolon complicating pseudomem-branous enterocolitis. Dis Colon Rectum 1995;138:1033-1038
15. Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology 1981;80:693-696
16. Kalkanci A, Tuncer C, Degertekin B, et al. Detection of Candida albicans by culture, serology and PCR in clinical specimens from patients with ulcerative colitis: re-evaluation of an old hypothesis with a new perspective. Folia Microbiol (Praha) 2005;50:263-267
17. Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002;78:455-459
18. Brook I. Pseudomembranous colitis in children. J Gastroenterol He-patol 2005;20:182-186
19. Elliott B, Chang BJ, Golledge CL, et al. Clostridium difficile-associated diarrhoea. Intern Med J 2007;37:561-568